Abstract 1733P
Background
On 24th of February 2022 reality in Ukraine changed. Ukraine became a victim of unfair attack of the neighbouring county. It influenced civilian population hugely, including the most vulnerable - children, elderly and patients. Since then, cancer patients became fighters of two fights - malignant disease and external aggressor. After more than a year of this reality Ukrainian oncologists would like to remind international society that the problem is not solved, and Ukrainians desperately need support.
Methods
It is generalized description of situation in the sphere of oncology in Ukraine since 24th of February 2022.
Results
According to Ukraine's Minister of Health, Victor Lyashko, during the first year of the war in Ukraine 1218 hospitals were damaged, 540 - partially destroyed and 173 destroyed completely. Among them - oncological hospitals. More than a million (∼1.2) Ukrainians currently stay on temporary occupied territories of the country and do not have access to qualified medical care. Around 7 million people had to move to safer areas of the country to stay safe and thousands of cancer patients had to move abroad for further treatment. It influenced the oncological landscape significantly. Oncological centers currently have to deal with 70% more patients than before the war. Moreover, the quantity of advanced stage disease has risen dramatically because a lot of people just couldn’t get medical help in time. Therefore, it caused bigger pressure on the medical system, requiring even more resources when they are so limited. At the same time, all clinical trials were put on pause leaving patients with advanced and rare diseases with no options for further treatment. Luckily, international society is extremely friendly to Ukraine providing Ukrainians with shelters and supplies, both material and intellectual. It helped and is helping a lot. But unfortunately, war is not over, and help is still needed.
Conclusions
The aim of the work is to show how things were going during this year of war and how they are actually going now for word to realize that even during the hardest time there is a place for high quality medical care. That only became possible thanks to huge support of international society, but there is still a lot to do to rebuild and improve reality that was destroyed on 24th of February.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1757P - A real-world evaluation of the effectiveness of thermogram along with clinical breast examination in community-based breast cancer screening program
Presenter: Rahul Ravind
Session: Poster session 23
1758P - Body composition meets precision medicine: The prognostic value of sarcopenia in patients (pt) treated with Molecularly Targeted Agents (MTA)
Presenter: Cinta Hierro
Session: Poster session 23
1760P - Systematic review of quality of life (QoL) inclusion among endpoints, reporting and impact of QoL results in phase III non-inferiority trials of systemic treatments in oncology
Presenter: Jessica Paparo
Session: Poster session 23
1761P - Incidence of herpes zoster in cancer patients in Europe: A systematic review
Presenter: Inga Posiuniene
Session: Poster session 23
1762P - Are published data up-to-date? Analysis of time to publication in major oncological journals
Presenter: Pawel Sobczuk
Session: Poster session 23
1763P - The challenge for Cancer Trials Ireland (CTI) to sponsor NCI and non-EU sponsored trials in the EU
Presenter: Eibhlin Mulroe
Session: Poster session 23
1886P - Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)
Presenter: Craig Gedye
Session: Poster session 23
1887P - Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial
Presenter: Primo Lara
Session: Poster session 23
1888P - 24-month follow up of durvalumab and savolitinib combination in MET-driven clear cell and non-clear cell renal cancer
Presenter: Francesca Jackson-Spence
Session: Poster session 23